Regulatory oversight protects patients. Operational oversight protects timelines. The strongest clinical programs integrate both.
Overview
When sponsors think about European batch release, they think about the Qualified Person (QP). Under EU GMP Volume 4, Annex 13, the QP bears personal legal responsibility for certifying that each batch of investigational medicinal product (IMP) meets regulatory and Good Manufacturing Practice (GMP) requirements prior to release. Certification is one of the most stringent safeguards in the clinical supply chain. It exists to protect patient safety and regulatory integrity. But certification does not operate in isolation.
Behind every release decision sits a complex network of forecasting assumptions, IRT configurations, depot transfers, manufacturing timelines, packaging schedules, site inventory controls and blinding safeguards. When these operational elements drift out of alignment, even the most rigorous certification process becomes reactive rather than strategic.
True supply continuity requires more than compliance. It requires integration between regulatory authority and operational intelligence. That is where the integration between QP and Drug Supply Management becomes critical. Regulatory oversight protects patients. Operational oversight protects timelines. The strongest clinical programs integrate both.
When sponsors think about European batch release, they think about the Qualified Person. That is appropriate. In the EU and UK, QPs carry legal responsibility for certifying that each batch of investigational medicinal product meets regulatory and GMP requirements before release. Certification is a critical safeguard. It ensures that manufacturing, testing, and documentation meet the required standards to protect patient safety. But certification does not operate in isolation.
Behind every QP decision sits a complex network of forecasting assumptions, IRT configurations, depot transfers, site inventory levels, and blinding safeguards. When these elements drift out of alignment, even the most rigorous certification process becomes more reactive rather than strategic. True supply continuity requires more than compliance. It requires coordination between regulatory authority and operational intelligence.
Regulatory Authority: The QP as Patient Safeguard
The QP role remains one of the most stringent regulatory responsibilities in the clinical supply chain. Certification demands a comprehensive review of regulatory documentation, supply chain oversight, manufacturing records, stability data, and deviation management. Decisions cannot be overruled, and accountability is personal. This structure exists for one reason: patient safety.
However, QP certification confirms that a batch is compliant at the point of release. It does not control how supply is forecasted, distributed, buffered, or adjusted as enrollment patterns evolve. Those operational dynamics influence whether product reaches patients efficiently and without disruption.
When documentation arrives late, when supply assumptions change mid-study, or when shipment patterns become unpredictable, pressure increases across the system. Certification still protects the patient, but the path to release becomes more complex.
Operational Control: The DSM as Supply Stabilizer
This is where Drug Supply Management becomes essential. Clinical Drug Supply Managers operate upstream and in parallel with certification. They monitor inventory across depots and sites, refine IRT resupply parameters as enrollment shifts, coordinate depot-to-depot transfers, and anticipate shortfalls before they become emergencies.
In practice, this means:
- Continuous review of resupply triggers rather than static system settings
- Weekly shipment monitoring to detect emerging risks
- Inventory right-sizing to prevent both shortages and waste
- Alignment between manufacturing schedules, packaging timelines, and site demand
In large global trials, strategic supply oversight can have a measurable financial impact. Optimized shipment planning in a 100-plus site program has demonstrated multimillion-dollar cost avoidance by reducing urgent shipments and excess inventory. More importantly, it reduces operational stress on clinical teams and minimizes the risk of dosing interruptions. Strong DSM oversight does not replace certification. It reduces the friction surrounding it.
Where Fragmentation Creates Risk
Challenges emerge when regulatory and operational oversight are disconnected. If QP services are isolated from supply planning, documentation readiness may not align with manufacturing cadence. If IRT parameters are configured once and not revisited, enrollment drift can trigger unplanned shipments or site imbalances. If supply communication flows through multiple uncoordinated channels, delays compound quickly.
Fragmentation rarely appears dramatic at first. It surfaces gradually as:
- Increased emergency shipments
- Excess on-site inventory
- Documentation backlogs
- Escalations during batch release
Each issue alone may seem manageable. Collectively, they strain timelines, budgets, and internal teams. An integrated oversight model reduces these cumulative pressures.
Integrated Oversight: A Continuity Model
Clinical supply continuity is not the responsibility of a single function. It is the result of multiple disciplines working in concert across the supply chain. A batch can be certified on time yet still fails to reach the patient when inventory assumptions are inaccurate. Manufacturing can remain on schedule, yet sites can experience shortages when enrollment outpaces forecasts. An IRT can execute exactly as configured yet still create operational challenges if supply parameters are noted reviewed as study conditions evolve.
Supply continuity is strongest when QP expertise, Drug Supply Management, manufacturing strategy, IRT configuration, and logistics planning operate within a coordinated framework.
Each function addresses a difference source risk:
- QP oversight safeguards product quality, compliance, and patient safety.
- Drug Supply Management provides ongoing operational control and supply optimization.
- Manufacturing ensures product availability and release readiness.
- IRT Systems execute randomization, inventory management, and supply allocation strategies.
- Logistics planning ensures product reaches depots and sites efficiently.
Certification must remain independent and uncompromised. Operational planning must remain adaptive. When regulatory authority and supply execution are Aligned alongside manufacturing cadence and distribution strategy, variability becomes manageable rather than disruptive.
An integrated oversight model includes:
- Embedded QP expertise across EU and UK markets
- DSM consultancy that scales based on project complexity and study lifecycle requirements
- Clear documentation pathways that facilitate efficient batch certification and release
- Adaptive supply strategies that evolve with enrollment trends, protocol amendments, and changing inventory demands.
- Continuous communication between quality, supply, manufacturing, and logistics stakeholders.
The result is not simply regulatory compliance. It is a more resilient clinical supply chain that reduces operational friction, minimizes emergency interventions, and helps ensure uninterrupted treatment throughout the study.
Continuity Through Coordination
Supply continuity is not achieved through certification alone. It is achieved through the coordination of regulatory oversight and operational execution through the lifecycle of a trial.
The Qualified Person protects patient safety by ensuring that investigational product meets regulatory and GMP requirements before release. Drug Supply Managers protect continuity by ensuring that products remain available where and when it is needed as study conditions evolve. Neither function replaces the other. Each addresses a different source of risk.
When regulatory authority and operational oversight operate within a coordinated framework, sponsors benefit from greater release readiness, fewer emergency logistics events, reduced inventory waste, stronger protection of blinding integrity, and improved confidence in their overall strategy.
Most importantly, they gain stability. Patients receive uninterrupted treatment; study teams operate with fewer surprises, and supply challenges are addressed before they become critical events. In an environment where enrollment fluctuates, protocols evolve, and global supply chains face constant pressure, continuity depends on more than compliance alone. It depends on the ability to align certification activities, supply planning, inventory management, and operational decision-making around a common objective.
Because in the end, continuity is not defined by a certification signature. It is defined by the ability to consistently deliver the right product to the right patient at the right time. Certification protects the patient. Operational oversight protects the study. The strongest clinical programs are built on both.
For further reading
- The Operational Backbone of Clinical Supply: Why DSMs Matter More Than Ever
About the Authors
Melissa Peirsel is Manager of Global IRT Services at Sharp Clinical Services, where she leads the teams responsible for the delivery, validation, and operational support of clinical trial technology solutions for sponsors worldwide. With more than 13 years of experience in clinical research, she specializes in interactive response technology (IRT), RTSM, randomization and blinding strategy, clinical supply operations, quality systems, and operational oversight for complex global and early phase clinical trials.
Her work focuses on translating clinical and operational complexity into practical solutions that balance regulatory expectations with the realities faced by clinical sites. She believes successful study design should simplify operations, protect blinding, and ultimately help investigators focus on what matters most: delivering treatment safely and efficiently to patients. Read more of her work in our Expert Content on Sharp’s website.
Basem Farhat is a Clinical Drug Supply Management Consultant at Sharp Clinical with more than 15 years of experience helping sponsors navigate the operational complexities of global clinical trials. Having supported more than 80 Phase I to III studies across biotech, pharmaceutical, CRO, and depot environments, he specializes in developing adaptive supply strategies that protect continuity, reduce waste, and keep investigational products available where and when patients need it. His expertise spans clinical supply forecasting, packaging, global distribution, temperature-controlled logistics, and IRT-supported supply management. Basem is passionate about translating operational complexity into practical supply strategies that help sponsors reduce risk throughout the clinical trial lifecycle.
Basem holds a Bachelor of Science degree from Penn State University.
